NASDAQ Heavily traded Stocks -PSDV, NTRS, OCZ, QLIK, VVUS
pSivida Corp. (NASDAQ: PSDV) percentage change dropped -48.47%, to close at $2.03 and its overall traded volume was 1.33M shares during the last session with the total traded volume of 97,181.00 shares. PSDV opened at $3.90 and is trading within the range of $1.40-$3.94. The stock has a 52-week range of $1.40-$7.22. At current market price, the market capitalization of the company stands at $42.13M and it has 20.80M outstanding shares.
pSivida Corp. develops drug delivery products that are administered by implantation, injection or insertion. Once administered, a drug is released on a controlled and level basis for months or years. The Company has two core technology systems, Durasert and BioSilicon. pSivida Corp. has one product candidate for chronic eye disease that has been given Priority Review by the United States Food and Drug Administration (FDA). It has a collaboration with Pfizer, Inc. (Pfizer) to develop additional ophthalmic products. Iluvien, the product candidiate with Priority Review, is designed to provide sustained release treatment for Diabetic Macula Edema (DME). Iluvien is licensed to Alimera Sciences, Inc (Alimera), which is completing fully-recruited Phase III clinical trials.
Northern Trust Corporation (NASDAQ: NTRS) moved up 3.09%, to close at $40.02 and its overall traded volume was 1.33M shares during the last session with the total traded volume of 2.55M shares. NTRS shares were trading within the range of $39.40-$40.16 while its opening price was $39.50. The 52-week range of the stock is $33.20-$56.86. At current market price, the market capitalization of the company stands at $9.64B and it has 241.00M outstanding shares. Northern Trust Corporation (Northern Trust) is a financial holding company. Northern Trust provides asset servicing, fund administration, investment management, banking and fiduciary solutions for corporations, institutions and individuals worldwide. The Company conducts business through various United States and non United States subsidiaries, including The Northern Trust Company (Bank). Northern Trust has organized its services globally around its two client-focused principal business units: Corporate and Institutional Services (CIS), and Personal Financial Services (PFS). Two other business units provide services to the two principal business units: Northern Trust Global Investments (NTGI), which provides investment management, and Operations and Technology (OT), which provides operating and systems support. In December 2010, the Company acquired Waterline Partners, LLC.
OCZ Technology Group Inc. (NASDAQ: OCZ) moved up 4.31%, to close at $7.99 and its overall traded volume was 1.32M shares during the last session with the total traded volume of 1.90M shares. OCZ opened at $7.80 and is trading within the range of $7.60-$8.00. The stock has a 52-week range of $3.80-$10.94. OCZ’s market capitalization is $413.50M and it has 51.75M outstanding shares. OCZ Technology Group, Inc. (OCZ) is a provider of high performance solid state drives (SSDs) and memory modules for computing devices and systems. In addition to its SSD and Memory Module product lines, the Company also designs, develops, manufactures and distributes other high performance components for computing devices and systems, including thermal management solutions and alternating current/direct current switching power supply units. The Company offers its customers flexibility and customization by providing a range of solutions, which are interoperable and can be configured alone or in combination to make computers run faster. Through its diversified and global distribution channel, it offers more than 450 products to 376 customers, including retailers, online retailers, original equipment manufacturers and computer distributors. In February 2010, OCZ divested its Hypersonic Personal Computer Systems product lines. In March 2011, the Company acquired Indilinx Co., Ltd.
Qlik Technologies Inc (NASDAQ: QLIK) moved up 2.64%, to close at $30.31 and its overall traded volume was 1.32M shares during the last session with the total traded volume of 1.44M shares. QLIK opened at $29.93 and is trading within the range of $29.56-$30.95. The stock has a 52-week range of $19.59-$35.62. The market capitalization of the company stands at $2.53B and it has 83.61M outstanding shares. Qlik Technologies Inc. (QlikTech), through its wholly owned subsidiaries, the Company sells software solutions that deliver data analysis and reporting solutions. QlikTech’s software platform, QlikView, combines enterprise-class analytics and search functionality. The Company’s solution addresses the needs of a range of customers from middle market customers to large enterprises, such as Autodesk, Campbell Soup Company, Colonial Life, The Dannon Company, Inc., Heidelberger Druckmaschinen AG, ING, Kraft Foods, Lifetime Brands, Nasdaq OMX, National Health Service (NHS), Qualcomm, Symantec and Volvo Car UK Limited. It has customers in over 100 countries, and approximately 75% of its revenue, during the year ended December 31, 2010, was derived internationally. On January 22, 2010, QlikTech acquired Syllogic Corporation (Syllogic).
VIVUS, Inc. (NASDAQ: VVUS) went up 3.01%, to close at $9.92 and its overall traded volume was 1.32M shares during the last session the stock had average daily volume of 1.29M shares. VVUS shares were trading within the range of $9.63-$10.14 while its opening price was $9.71. The stock has a 52-week range of $6.00-$11.48. VVUS’s market capitalization is $881.71M and it has 88.88M outstanding shares. VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in development and commercialization of therapeutic drugs for large underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes and men’s sexual health. As of December 31, 2010, it had one investigational drug candidate, QNEXA, which has been submitted for approval as a treatment for weight loss in the United States and the European Union. In the United States, it received a complete response letter for QNEXA in October 2010, which contained requests for additional information. As of December 31, 2010, it also had investigational drug candidates in various stages of clinical development for various indications related to obesity, erectile dysfunction and other diseases. On November 5, 2010, it sold certain rights and assets related to MUSE, transurethral alprostadil, for the treatment of erectile dysfunction to Meda AB. On October 14, 2011, Polycom, Inc. acquired the Company.
Article source: http://www.retirementplannings.org/nasdaq-heavily-traded-stocks-psdv-ntrs-ocz-qlik-vvus-11543